WARPTECHNEWS · LAB

Home AI Business Tech Archive

WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

Home
Archivio
Editor's Brief
Cerca
Il tuo account
Newsletter tech/AI

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

China’s drugmakers to take the stage at ASCO

It’s no secret that Akeso’s presentation will be one of the most closely watched readouts from the American Society of Clinical Oncology annual meeting this year.

giovedì 21 maggio 2026 New tab

131 words~1 min read

May 21, 2026 11:39 AM EDT

R&DChina

China’s drugmakers to take the stage at ASCO

Lei Lei Wu

News Reporter

Other newsrooms on this story

· 3 sources

Full timeline →

biopharmadive.com·May 22, 2026 · 1 mesi fa
ASCO26: 5 data snapshots ahead of the year’s biggest cancer drug meeting
morningstar.com·May 26, 2026 · 1 mesi fa
Over 40 Studies Featuring Akeso's Innovative Oncology Agents to Be Presented at ASCO 2026: Ivonescimab's HARMONi-6 Overall Survival Data Selected for Plenary Session
statnews.com·May 22, 2026 · 1 mesi fa
EU and US advisers split over AstraZeneca breast cancer drug

Related reading

Exclusive: Akeso pushes back on ASCO questioning of lung cancer drug

Akeso CEO Michelle Xia tells Endpoints the scrutiny of Chinese vs. Western patient data for ivonescimab is overblown, with the…

endpoints.news·15 g fa

fiercepharma.com

As Akeso takes center stage at ASCO, China biotech industry cements its coming…

In 2017, a little-known company called Nanjing Legend Biotech walked into the ASCO annual meeting at the 11th hour, dropped a…

fiercepharma.com·1 mesi fa

fiercepharma.com

ASCO preview: With expectations jacked up, Akeso's ivonescimab to face scrutiny…

Placement on the plenary session of the upcoming ASCO 2026 annual meeting has significantly elevated enthusiasm around Akeso’s…

fiercepharma.com·1 mesi fa

fiercepharma.com

ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos,…

It’s the moment of truth for Akeso’s ivonescimab, and to many, a high-stakes test for China’s booming biotech industry. |…

fiercepharma.com·1 mesi fa

fiercepharma.com

Behind the headlines of ASCO 2026

Each year, the global oncology community flocks to Chicago to convene at the American Society of Clinical Oncology’s ann | Each…

fiercepharma.com·1 mesi fa

A turning point for pancreatic cancer patients

Eli Lilly announces two China deals, Akeso's lung cancer bispecific payoff, and more biotech news from The Readout

statnews.com·1 mesi fa